Perioperative immunotherapy combined with standard therapy for human epidermal growth factor receptor 2-positive locally advanced gastric cancer: A case report

doi:10.5306/wjco.v16.i11.112029

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=0

Nov 24, 2025 (publication date) through Nov 21, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Oncol. Nov 24, 2025; 16(11): 112029
Published online Nov 24, 2025. doi: 10.5306/wjco.v16.i11.112029

Open in New Tab Full Size Figure Download Figure

Figure 1 Computed tomography imaging changes. A total of 4 cycles of oxaliplatin, S-1 combined with trastuzumab were received. A: Before treatment; B: After treatment.

Citation: Ma XT, Yao GY, Li JL, Wang XC, Ba Y. Perioperative immunotherapy combined with standard therapy for human epidermal growth factor receptor 2-positive locally advanced gastric cancer: A case report. World J Clin Oncol 2025; 16(11): 112029
URL: https://www.wjgnet.com/2218-4333/full/v16/i11/112029.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i11.112029